9 recruiting, 6 completed, 5 unknown, 1 active not recruiting. 10 Phase 2, 7 Phase 1, 5 Early Phase 1, 1 Not applicable.
Follow 68Ga-Dotatate: new trials by email Literature Review of 68Ga-Dotatate trials Research Report on 68Ga-Dotatate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 10 | 2026-06-30 | 2026-06-05 |
| Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake 68Ga-Dotatate - Healthy (Controls), Healthy Volunteers | Phase 2 | Recruiting | Akiva Mintz | 200 | 2025-12-11 | 2026-04-08 |
| RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography - Recurrent Meningioma | Phase 1 / Phase 2 | Recruiting | Joshua Palmer | 30 | 2025-11-12 | 2026-08-13 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET - Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-02-07 | 2026-10-16 |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE - Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 35 | 2023-12-27 | 2026-10-14 |
| Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma 68Ga-MGS5 - Medullary Thyroid Carcinoma | Phase 1 | Unknown | First Affiliated Hospital of Fujian Medical University | 20 | 2023-06-21 | 2024-07-25 |
| Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors Al18F-NOTA-LM3, 68Ga-DOTATATE, 68Ga-NODAGA-LM3 - Neuroendocrine Tumors | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 80 | 2023-03-23 | 2025-04-02 |
| 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor 18F-MFBG, 68Ga-Dotatate - Neuroendocrine Tumor, Neuroblastoma | Early Phase 1 | Recruiting | Peking Union Medical College Hospital | 150 | 2021-09-01 | 2024-03-01 |
| Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging - Grade 1 Meningioma, Grade 2 Meningioma | Phase 2 | Recruiting | Mayo Clinic | 42 | 2020-04-14 | 2026-10-13 |
| Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO 68Ga-Dotatate, 68Ga-DOTA-JR11 - Tumor-Induced Osteomalacia | Phase 1 | Unknown | Peking Union Medical College Hospital | 50 | 2020-03-15 | 2021-01-05 |
| Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract 68Ga-DOTATATE, Positron Emission Tomography (PET) Scan - Neuroendocrine Carcinoma | Completed | H. Lee Moffitt Cancer Center and Research Institute | 30 | 2019-09-25 | 2026-03-31 | |
| An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography - Ganglioneuroblastoma, Ganglioneuroma | Early Phase 1 | Active not recruiting | Mayo Clinic | 20 | 2019-09-23 | 2026-03-31 |
| Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography - Meningioma | Phase 1 | Completed | M.D. Anderson Cancer Center | 13 | 2019-01-10 | 2023-09-01 |
| Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Completed | Emory University | 17 | 2018-02-22 | 2025-07-17 |
| 68Ga-DOTATATE PET/CT in Neuroendocrine Tumor 68Ga-DOTATATE - Neuroendocrine Tumors | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 100 | 2014-04-01 | 2019-08-01 |
| Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome DOTATATE PET-CT, F-DOPA PET CT, CT scan - ACTH, Cushing's Syndrome | Phase 2 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 80 | 2014-02-12 | 2026-10-02 |
| Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective 68Ga-DOTATATE - Neuroendocrine Tumors | Early Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 100 | 2013-08-26 | 2024-07-19 |
| 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs) 68Ga-DOTATATE, PET/CT, 111In-pentetreotide OctreoScan - Neuroendocrine Carcinoma | Not applicable | Completed | Radio Isotope Therapy of America | 169 | 2013-03-01 | 2025-08-06 |
| 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia 68Ga-DOTATATE - Oncogenic Osteomalacia, Mesenchymal Tumor | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 100 | 2011-12-01 | 2017-04-07 |
Showing 20 of 21. Sign in to see all of them.
Neuroendocrine Tumors (4) · Meningioma (3) · Paraganglioma (3) · Pheochromocytoma (3) · Carcinoma, Neuroendocrine (2) · Neuroblastoma (2) · Oncogenic osteomalacia (2) · Prostatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Medullary (1) · Cushing Syndrome (1) · Esthesioneuroblastoma, Olfactory (1) · Ganglioneuroblastoma (1) · Ganglioneuroma (1) · Head and Neck Neoplasms (1)
Peking Union Medical College Hospital (5) · National Cancer Institute (NCI) (3) · Mayo Clinic (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Akiva Mintz (1) · Emory University (1) · First Affiliated Hospital of Fujian Medical University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Joshua Palmer (1) · M.D. Anderson Cancer Center (1) · OHSU Knight Cancer Institute (1) · Radio Isotope Therapy of America (1)
United States (15) · China (6)
Frank I Lin, M.D. (2) · Ebrahim Delpassand, MD (1) · Fang Li (1) · Fang Li, MD (1) · Hongli Jing, MD (1) · Jason M Johnson (1) · Johannes Czernin, MD (1) · John M Floberg (1) · Jonathan Strosberg, MD (1) · Joshua D Palmer, MD (1) · Kenneth W. Merrell, MD (1) · Lynnette K Nieman, M.D. (1) · Mehmet Asim Bilen, MD (1) · Meixi Liu, MD (1) · Nadia Laack, MD (1)
PMID 34146130, PMID 35280786, PMID 37160439, PMID 38878175, PMID 40717185, PMID 40762797
UM1CA186691 (1)